組み換えワクチンの市場規模、シェア、成長分析：タイプ別、疾患別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025～2032年

組み換えワクチンの2023年の市場規模は100億5,000万米ドルで、予測期間（2025～2032年）のCAGRは11.4%で、2024年の112億米ドルから2032年には265億5,000万米ドルに成長する見通しです。

2023年10月現在、ワクチン市場は遺伝子工学、ゲノミクス、組換えDNA技術の進歩による変革期を迎えています。従来のワクチンは、主に病原体の減衰や不活性化による暴露戦略を利用していましたが、徐々に革新的な実験室開発の代替ワクチンに取って代わられつつあります。これらの新しいワクチンは、遺伝子スクリーニング技術を活用して感染症に関連するリスクを効果的に除去し、ワクチン接種プロセスにおける有効性と安全性の両方を高めています。この進化は、公衆衛生の成果を高める、より正確で的を絞ったアプローチを提供する、予防接種における極めて重要な瞬間を意味します。最先端技術のワクチン開発への統合は、市場の展望を広げるだけでなく、ヘルスケア分野における予防接種の実践に新たな基準を設定します。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

組み換えワクチン市場規模：タイプ別

• 市場概要
• サブユニット組み換えワクチン
• 弱毒化組み換えワクチン
• ベクター組み換えワクチン

組み換えワクチン市場規模：疾患別

• 市場概要
• 肺炎球菌感染症
• がん
• B型肝炎
• インフルエンザ
• 二酸化ケイ素
• その他

組み換えワクチン市場規模：エンドユーザー別

• 市場概要
• 小児
• 成人
• 高齢者

組み換えワクチン市場規模：流通チャネル別

• 市場概要
• 病院および薬局
• 政府サプライヤー

組み換えワクチン市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Moderna, Inc.（United States）
• Novavax, Inc.（United States）
• Johnson & Johnson（United States）
• AstraZeneca plc（United Kingdom）
• Bavarian Nordic A/S（Denmark）
• BioNTech SE（Germany）
• Vaxart, Inc.（United States）
• Transgene S.A.（France）
• GeoVax Labs, Inc.（United States）
• Vaxcyte, Inc.（United States）
• Green Cross Corporation（GC Biopharma）（South Korea）
• Bharat Biotech International Limited（India）
• Shantha Biotechnics Limited（India）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（United States）
• Sinovac Biotech Ltd.（China）

結論と提言

Recombinant Vaccines Market size was valued at USD 10.05 billion in 2023 and is poised to grow from USD 11.2 billion in 2024 to USD 26.55 billion by 2032, growing at a CAGR of 11.4% during the forecast period (2025-2032).

As of October 2023, the vaccine market is undergoing a transformative shift driven by advancements in genetic engineering, genomics, and recombinant DNA technologies. Traditional vaccines, which primarily utilized exposure strategies through pathogen attenuation or inactivation, are gradually giving way to innovative laboratory-developed alternatives. These new vaccines harness genetic screening techniques to effectively remove the risks associated with infectious diseases, ensuring both efficacy and heightened safety in vaccination processes. This evolution signifies a pivotal moment in immunization, offering a more precise and targeted approach that enhances public health outcomes. The integration of cutting-edge technology into vaccine development not only broadens the market landscape but also sets new standards for immunization practices in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

A key driver of growth in the recombinant vaccines market is the widespread use of recombinant technology, which significantly boosts both the effectiveness and safety of vaccines given to patients. This technology allows for the swift and large-scale production of vaccines, reducing the chances of supply shortages. Additionally, recombinant vaccines do not contain infectious viral particles, which decreases the risk of infection and makes them suitable for individuals with weakened immune systems. The advantages of these vaccines have prompted manufacturers to invest in the development of innovative solutions aimed at viral diseases, utilizing advanced DNA technology, genomics, and state-of-the-art biotechnology techniques to create safer and more effective vaccines.

Restraints in the Recombinant Vaccines Market

The growth of the recombinant vaccines market is hindered by multiple challenges, particularly the high cost associated with each dose, which poses a substantial barrier to widespread adoption. Although international organizations are actively working to enhance global vaccination efforts by distributing millions of doses in various regions, the steep price of these vaccines limits accessibility for numerous populations. As a result, despite ongoing initiatives aimed at ensuring equitable distribution, certain areas still struggle to overcome the financial obstacles tied to vaccination. This situation creates significant disparities in vaccine access, ultimately impacting public health outcomes across different demographics.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is witnessing significant growth driven by the rising prevalence of infectious diseases and the urgent need for effective immunization strategies, particularly for vulnerable populations such as the elderly and children. Efforts led by international organizations, including UNICEF and PAHO, to ensure the rapid distribution of vaccines in emergency situations have underscored the critical role of recombinant technologies in enhancing vaccine efficacy and accessibility. This trend not only reflects the global commitment to public health but also highlights advancements in vaccine development, which are pivotal in strengthening community immunity and curbing disease outbreaks worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2025-2032)

• Market Overview
• Subunit recombinant vaccines
• Attenuated recombinant vaccines
• Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Pneumococcal Disease
• Cancer
• Hepatitis B
• Influenza
• DPT
• Others

Global Recombinant Vaccines Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital & Retail Pharmacies
• Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2025-2032)

• North America (Type, Disease, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Disease, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Disease, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Disease, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Disease, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (GC Biopharma) (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shantha Biotechnics Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations